Another Win for SGLT2 Inhibitors in Chronic Kidney Disease

Chronic kidney disease affects 14% of the U.S. population1 and is associated with an extraordinarily high risk of poor outcomes, including progression to end-stage kidney disease, cardiovascular events, and death.2 Finally, after decades of therapeutic stagnation, a recent explosion of new therapies has revolutionized treatment options in this vulnerable patient population. Prominent among these therapies are the sodium–glucose cotransporter 2 (SGLT2) inhibitors, as described in landmark trials, including the EMPA-KIDNEY trial of empagliflozin in 2023.3 In this issue of the Journal,4 Herrington et al. report the long-term results of the EMPA-KIDNEY follow-up trial involving patients with chronic kidney disease who . . .